The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare's list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to negotiate,

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.

Wegovy, Ozempic added to list of drugs where the federal government will try winning discounts from manufacturers.

WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.

The popular weight-loss drugs were added to Medicare’s list of prices negotiated directly between the government and drug manufacturers.